Secretory phospholipase: A potential target for cardiovascular therapies

Stephen J. Nicholls, MyNgan Duong

Research output: Contribution to journalArticle

Abstract

Increasing evidence implicates the activation of inflammatory pathways in the pathogenesis of cardiovascular disease. Accordingly, there is considerable interest in the development of new cardioprotective therapies that target inflammatory factors that promote the progression of heart disease. Secretory phospholipase A2 (sPLA2) generates a range of fatty acid and prostaglandin metabolites that play a pivotal role in the molecular events involved in the formation, progression and rupture of atherosclerotic plaque. The findings of sPLA2 in atherosclerotic plaque, accelerated disease in transgenic models and association between elevated sPLA2 levels in plasma and adverse cardiovascular events in population studies suggest that the pharmacological inhibition of sPLA2 may be beneficial. The early experience with the clinical development of sPLA2 inhibitors to reduce cardiovascular risk will be reviewed.

LanguageEnglish
Pages22-26
Number of pages5
JournalHeart and Metabolism
Issue number60
Publication statusPublished - Sep 2013

Keywords

  • Cardiovascular disease
  • Inflammation
  • Risk factor
  • SPLA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Nicholls, Stephen J. ; Duong, MyNgan. / Secretory phospholipase : A potential target for cardiovascular therapies. In: Heart and Metabolism. 2013 ; No. 60. pp. 22-26.
@article{819d6306ef60422ab5b789beb0cf93a9,
title = "Secretory phospholipase: A potential target for cardiovascular therapies",
abstract = "Increasing evidence implicates the activation of inflammatory pathways in the pathogenesis of cardiovascular disease. Accordingly, there is considerable interest in the development of new cardioprotective therapies that target inflammatory factors that promote the progression of heart disease. Secretory phospholipase A2 (sPLA2) generates a range of fatty acid and prostaglandin metabolites that play a pivotal role in the molecular events involved in the formation, progression and rupture of atherosclerotic plaque. The findings of sPLA2 in atherosclerotic plaque, accelerated disease in transgenic models and association between elevated sPLA2 levels in plasma and adverse cardiovascular events in population studies suggest that the pharmacological inhibition of sPLA2 may be beneficial. The early experience with the clinical development of sPLA2 inhibitors to reduce cardiovascular risk will be reviewed.",
keywords = "Cardiovascular disease, Inflammation, Risk factor, SPLA",
author = "Nicholls, {Stephen J.} and MyNgan Duong",
year = "2013",
month = "9",
language = "English",
pages = "22--26",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Imprimerie Jouve",
number = "60",

}

Secretory phospholipase : A potential target for cardiovascular therapies. / Nicholls, Stephen J.; Duong, MyNgan.

In: Heart and Metabolism, No. 60, 09.2013, p. 22-26.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Secretory phospholipase

T2 - Heart and Metabolism

AU - Nicholls, Stephen J.

AU - Duong, MyNgan

PY - 2013/9

Y1 - 2013/9

N2 - Increasing evidence implicates the activation of inflammatory pathways in the pathogenesis of cardiovascular disease. Accordingly, there is considerable interest in the development of new cardioprotective therapies that target inflammatory factors that promote the progression of heart disease. Secretory phospholipase A2 (sPLA2) generates a range of fatty acid and prostaglandin metabolites that play a pivotal role in the molecular events involved in the formation, progression and rupture of atherosclerotic plaque. The findings of sPLA2 in atherosclerotic plaque, accelerated disease in transgenic models and association between elevated sPLA2 levels in plasma and adverse cardiovascular events in population studies suggest that the pharmacological inhibition of sPLA2 may be beneficial. The early experience with the clinical development of sPLA2 inhibitors to reduce cardiovascular risk will be reviewed.

AB - Increasing evidence implicates the activation of inflammatory pathways in the pathogenesis of cardiovascular disease. Accordingly, there is considerable interest in the development of new cardioprotective therapies that target inflammatory factors that promote the progression of heart disease. Secretory phospholipase A2 (sPLA2) generates a range of fatty acid and prostaglandin metabolites that play a pivotal role in the molecular events involved in the formation, progression and rupture of atherosclerotic plaque. The findings of sPLA2 in atherosclerotic plaque, accelerated disease in transgenic models and association between elevated sPLA2 levels in plasma and adverse cardiovascular events in population studies suggest that the pharmacological inhibition of sPLA2 may be beneficial. The early experience with the clinical development of sPLA2 inhibitors to reduce cardiovascular risk will be reviewed.

KW - Cardiovascular disease

KW - Inflammation

KW - Risk factor

KW - SPLA

UR - http://www.scopus.com/inward/record.url?scp=84891938614&partnerID=8YFLogxK

M3 - Article

SP - 22

EP - 26

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 60

ER -